Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Resistance
Computer models predict how patients will respond to HIV drugs

Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.

Published
14 March 2013
From
Eurekalert Inf Dis
Changing treatment
PI monotherapy for HIV — an idea whose time has passed?

Patients who switched from suppressive triple-drug therapy to boosted protease-inhibitor monotherapy had unreasonably high rates of treatment failure.

Published
05 December 2012
From
Journal Watch
Changing treatment
Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

Published
13 November 2012
From
International AIDS Society
Treatment interruptions
Pegylated interferon may maintain HIV suppression and reduce viral DNA integration

Adding pegylated interferon alfa to antiretroviral therapy (ART) for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases.

Published
12 November 2012
From
HIVandHepatitis.com
New and experimental HIV treatments
Is protease inhibitor monotherapy sufficient to keep HIV under control in the brain?

Researchers in Sweden and Switzerland have been conducting clinical trials of PI monotherapy and HIV-related neurological research. Recently, two teams have separately reported that their data strongly suggest that injury to cells within the brain has occurred in some participants when exposed to PI monotherapy. The Swedish team recommends that PI monotherapy be used cautiously until further clinical trials are completed and more detailed information on the brain health of participants becomes available.

Published
02 November 2012
From
CATIE
Treatment-experienced people
Booster HIV Drug Can Be Dropped

In a randomized trial, switching away from the booster drug allowed treatment-experienced patients to keep HIV under control and reduced toxicity, according to David Wohl, MD, of the University of North Carolina in Chapel Hill.

Published
13 September 2012
From
MedPage Today
HIV treatment in children
FDA Approves INTELENCE® (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1

Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved INTELENCE® (etravirine) to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced pediatric patients (6 years to less than 18 years old) who are experiencing virologic failure with HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other ARVs.

Published
28 March 2012
From
Janssen press release
Pharmaceutical industry
Gilead inks one combo HIV drug pact as it explores new ties with J&J -

Under a new pact Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. The companies also outlined ongoing talks on a separate pact  on the development and commercialization of a future single-tablet regimen combining Prezista with Gilead's Emtriva, its experimental GS 7340 and cobicistat. Gilead would be responsible for the development and commercialization of the new STR on a worldwide basis.

Published
28 June 2011
From
FierceBiotech
Changing treatment
International team to investigate second-line HIV therapy in Africa

The largest clinical trial to investigate treatment options for individuals whose first combination of anti-HIV medicines is no longer working has been announced following the recruitment of 1,200 HIV-positive individuals from across five African

Published
18 May 2011
From
University College Dublin
Treatment-experienced people
Drug Resistance Shouldn’t Preclude Using NRTIs in an HIV Salvage Regimen

People with heavily drug-resistant HIV benefit from adding two nucleoside reverse transcriptase inhibitors (NRTIs) to a regimen that contains Isentress (raltegravir), even if their virus is partially or fully resistant to the NRTIs. These data were published online January 28 in the Journal of Acquired Immune Deficiency Syndromes.

Published
02 February 2011
From
AIDSMeds
← First12Next →

Filter by country